Table 4. Treatment response of patients evaluated by CT.
| Variable | R + PGLD group (n=74) | T + P group (n=74) | P value |
|---|---|---|---|
| Lipiodol deposition | 0.785 | ||
| Dense | 29 (39.2%) | 31 (41.9%) | |
| Partial | 34 (45.9%) | 30 (40.5%) | |
| Sparse | 11 (14.9%) | 13 (17.6%) | |
| CR | 8 (10.8%) | 4 (5.4%) | 0.367 |
| PR | 40 (54.1%) | 30 (40.5%) | 0.138 |
| SD | 18 (24.3%) | 21 (28.4%) | 0.709 |
| PD | 6 (8.1%) | 12 (16.2%) | 0.208 |
| MD | 2 (2.7%) | 7 (9.5%) | 0.166 |
| OR (CR + PR) | 48 (64.9%) | 34 (45.9%) | 0.031 |
| DC (CR + PR + SD) | 66 (89.2%) | 55 (74.3%) | 0.032 |
R + PGLD, raltitrexed plus polyethylene glycol liposomal doxorubicin; T + P, tegafur plus pirarubicin; CR, complete response; SD, stable disease; PD, progressive disease; MD, Metastatic disease; OR, objective response; DC, disease control.